GlobalData’s April CPMI shows resilience masking pre-execution caution, with conflict risk surfacing unevenly by country and sector.

Conio’s MiCAR authorization signals regulators are moving from warning to enabling. Here’s what boards should watch next.

Advisers tell the FDA Moderna’s benefits outweigh risks, a regulatory green-light move that could reshape seasonal influenza.

A wave of lawsuits is reshaping how US electric aircraft companies defend technology, capital, and timelines.

Early human results suggest a new kind of calorie burn aimed at protecting lean mass, in a field under FDA pressure.

Her Instagram Stories claim sets off a bigger fight over consent, copyright, and the growing AI track pipeline.

In a Bloomberg interview, the Signal president draws hard lines on trust, sentience, and Microsoft-style agent access.

The move uses fandom as demand fuel, betting novelty drink drops can outperform traditional machine-only sales.

A 57-year-old North Carolina man is accused of manufacturing a $3 billion backer story to take control.

The format launched months ago, and Viu is building a broader branded and co-production plan around it.

More than 25 gigawatt-hours are slated for US and European builds, driven by energy shock and grid upgrades.

Creditors and film workers lose the entity they need to pursue unpaid fees, after 50 of Alan Latham’s businesses are removed.